Capital One Financial Comments on Amphastar Pharmaceuticals, Inc.’s Q1 2024 Earnings (NASDAQ:AMPH)

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) – Research analysts at Capital One Financial issued their Q1 2024 earnings per share estimates for shares of Amphastar Pharmaceuticals in a report released on Wednesday, April 17th. Capital One Financial analyst T. Chiang anticipates that the company will post earnings of $0.72 per share for the quarter. The consensus estimate for Amphastar Pharmaceuticals’ current full-year earnings is $3.42 per share. Capital One Financial also issued estimates for Amphastar Pharmaceuticals’ Q2 2024 earnings at $0.72 EPS, Q3 2024 earnings at $1.01 EPS and Q4 2024 earnings at $1.03 EPS.

Several other equities research analysts have also recently issued reports on AMPH. StockNews.com cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. JPMorgan Chase & Co. assumed coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They set an “overweight” rating and a $60.00 target price for the company. Finally, Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, April 10th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $66.00.

Amphastar Pharmaceuticals Trading Down 3.5 %

Shares of AMPH stock opened at $38.65 on Thursday. The company has a current ratio of 2.17, a quick ratio of 1.70 and a debt-to-equity ratio of 0.92. The stock has a market cap of $1.89 billion, a price-to-earnings ratio of 14.98, a PEG ratio of 0.98 and a beta of 0.84. The company’s 50-day moving average price is $46.59 and its 200-day moving average price is $51.23. Amphastar Pharmaceuticals has a twelve month low of $35.62 and a twelve month high of $67.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.03). Amphastar Pharmaceuticals had a return on equity of 26.95% and a net margin of 21.34%. The company had revenue of $178.11 million for the quarter, compared to analyst estimates of $174.90 million.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. McGlone Suttner Wealth Management Inc. acquired a new position in shares of Amphastar Pharmaceuticals in the fourth quarter valued at approximately $28,000. Principal Securities Inc. purchased a new position in shares of Amphastar Pharmaceuticals during the 4th quarter worth approximately $34,000. Quadrant Capital Group LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 27.8% in the 4th quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock valued at $63,000 after buying an additional 223 shares during the period. Ronald Blue Trust Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 821.5% in the 3rd quarter. Ronald Blue Trust Inc. now owns 1,198 shares of the company’s stock valued at $55,000 after buying an additional 1,068 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Amphastar Pharmaceuticals by 99.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,261 shares of the company’s stock valued at $58,000 after buying an additional 628 shares in the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Floyd F. Petersen sold 500 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $53.10, for a total transaction of $26,550.00. Following the completion of the transaction, the director now directly owns 80,333 shares of the company’s stock, valued at $4,265,682.30. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 500 shares of the firm’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $53.10, for a total transaction of $26,550.00. Following the transaction, the director now owns 80,333 shares of the company’s stock, valued at $4,265,682.30. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Michael A. Zasloff sold 12,500 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total value of $589,750.00. Following the completion of the sale, the director now directly owns 21,326 shares of the company’s stock, valued at $1,006,160.68. The disclosure for this sale can be found here. Insiders have sold a total of 14,000 shares of company stock valued at $660,860 in the last ninety days. Company insiders own 28.40% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.